Innovative Medicine Backed by the Power of
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug development.
Neuroscience
BXCL501 is an investigational, proprietary, orally dissolving,
thin film formulation of dexmedetomidine designed for the
treatment of agitation and opioid withdrawal symptoms.
Immuno-Oncology
BXCL701 is an investigational, orally-administered, systemic
innate immunity activator in development for the treatment of
aggressive forms of prostate cancer and advanced solid tumors
that are refractory or treatment naïve to
checkpoint inhibitors.
May 20, 2022
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment ConferenceVIEW RELEASE
May 09, 2022
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational HighlightsVIEW RELEASE
May 05, 2022
BioXcel Therapeutics to Present at Three Upcoming Investor ConferencesVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
May 27, 2022 04:00 PM
MARKET/SYMBOL
BTAI
PRICE
12.25
CHANGE
0.71 (6.15%)
